CEO Kevin Tang purchases 814,606 shares totaling $12,455,227.01 across 5 transactions at $15.28–$15.35
Kevin Tang, CEO of Aurinia Pharmaceuticals, made 5 separate open-market purchases totaling 814,606 shares for $12,455,227.01 between May 29 and June 2, 2026, at a blended average price of $15.29, raising his holdings from 12,229,500 to 13,044,106 shares. This represents a 6.7% increase in his pre-transaction position at a company with strong fundamentals: $77,705,000 in latest quarterly revenue, $34,355,000 net income, 20.4% annual revenue growth, and a P/E of 6.63. His prior 5 purchases at AUPH were all well-timed at the 90-day mark, establishing a consistent pattern of buy timing at this ticker. The current stock price of $15.39 reflects minimal movement from the purchase window, positioning this filing for near-term market assessment against his demonstrated buying pattern.